GE HealthCare Reports Strong Q2 Earnings with 5.7% Revenue Growth

GE HealthCare delivered strong Q2 earnings, reporting a 5.7% revenue increase to $5.3 billion. The company's adjusted earnings per share (EPS) of $1.13 beat estimates, with the revenue and EPS growth driven by strong imaging demand and tariff refunds.

GE HealthCare Technologies reported Q2 2026 revenue of $5.3 billion, up 5.7% year over year, with organic revenue growth of 3.5%. Adjusted earnings per share of $1.13 beat the $1.04 analyst consensus and rose from $1.06 a year earlier.

Net income climbed to $561 million, lifted by $129 million in one-time IEEPA tariff refunds. Only $23 million of that refund reached adjusted EBIT, the metric behind the adjusted EPS beat; the other $106 million was excluded from adjusted results as non-recurring, and management does not expect comparable refunds in 2026.

Segment results were mixed. The newly combined Advanced Imaging Solutions unit grew revenue 7.9% to $3.77 billion, and Pharmaceutical Diagnostics jumped 15.6% to $843 million. Patient Care Solutions revenue fell 13.3% to $675 million with a negative segment profit. Organic orders rose 11.1%, pushing book to bill to 1.15x and the backlog to a record $23.9 billion.

GE HealthCare reaffirmed full year 2026 guidance of 3.0% to 4.0% organic revenue growth, adjusted EPS of $4.80 to $5.00, and about $1.6 billion in free cash flow. Shares rose roughly 2.5% as investors weighed the broad revenue and orders beat against the fading tariff tailwind and softer Patient Care Solutions segment.

Related Stocks

GEHC